HealthInnovent's IBI363 Receives Third NMPA Breakthrough Therapy Designation
Innovent Biologics announced that its drug IBI363, a PD-1/IL-2Α-bias bispecific fusion protein, has received its third Breakthrough Therapy Designation from China's NMPA for treating MSS/Pmmr metastatic colorectal cancer. The designation highlights the drug's potential in addressing this specific cancer type, marking a significant milestone for Innovent's biopharmaceutical development efforts.
Menafn·


